NIAGEN BIOSCIENCE INC
NAGENASDAQTrading Snapshot
- Day Range
- $3.02 – $3.11
- 52-Week Range
- $2.87 – $10.52
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 79.6M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $30M
- P/E Ratio
- 15.4
- P/S Ratio
- 1.9x
- EPS (TTM)
- $0.20
- Dividend Yield
- 0.00%
Why Investors Own NAGE
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NIAGEN BIOSCIENCE INC
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
LOS ANGELES, August 06, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com.
Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com
The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed NAD+ supplement to
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration compared with exercise based protocols. See our latest analysis for Niagen Bioscience. The recent clinical findings arrive after a difficult stretch for Niagen Bioscience’s stock. The 1 day share price return has fallen 14.7% and the year to date share price return has declined 52.64%. However,...
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential.
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
LOS ANGELES, August 04, 2026--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.